dicuno 25 mg apvalkotās tabletes
vitabalans oy, finland - diklofenaka kālija sāls - apvalkotā tablete - 25 mg
dicuno 50 mg apvalkotās tabletes
vitabalans oy, finland - diklofenaka kālija sāls - apvalkotā tablete - 50 mg
preventef 150 mg/g kaklasiksna
virbac s.a., francija - dimpylate - kaklasiksna - 150 mg/g - suņi
preventef 150 mg/g kaklasiksna
virbac s.a., francija - dimpylate - kaklasiksna - 150 mg/g - kaķi
metforal 500 mg ilgstošās darbības tabletes
berlin-chemie ag, germany - metformīna hidrohlorīds - ilgstošās darbības tablete - 500 mg
metforal 750 mg ilgstošās darbības tabletes
berlin-chemie ag, germany - metformīna hidrohlorīds - ilgstošās darbības tablete - 750 mg
metforal 1000 mg ilgstošās darbības tabletes
berlin-chemie ag, germany - metformīna hidrohlorīds - ilgstošās darbības tablete - 1000 mg
metforal 1000 mg apvalkotās tabletes
laboratori guidotti s.p.a., italy - metformīna hidrohlorīds - apvalkotā tablete - 1000 mg
metforal 1000 mg apvalkotās tabletes
laboratori guidotti s.p.a., italy - metformīna hidrohlorīds - apvalkotā tablete - 1000 mg
clopidogrel acino
acino ag - clopidogrel - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antitrombotiskie līdzekļi - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , , , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease, non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa), st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy, patients suffering from acute coronary syndrome. , ,.